Desmoid Tumors Market to Observe Stupendous Growth During the Forecast Period (2022-32) – DelveInsight | Key Companies – Ayala Pharmaceuticals (AL102), SpringWorks Therapeutics (Nirogacestat)

Desmoid Tumors Market to Observe Stupendous Growth During the Forecast Period (2022-32) - DelveInsight | Key Companies - Ayala Pharmaceuticals (AL102), SpringWorks Therapeutics (Nirogacestat)
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 12+ key pharma and biotech companies are working in the Desmoid Tumors therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

DelveInsight’s “Desmoid Tumors Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Desmoid Tumors Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Desmoid Tumors market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Desmoid Tumors Market

Desmoid Tumors: An Overview

Desmoid tumors is an abnormal growth that arises from connective tissue. “Desmoid” comes from the Greek word desmos, which means tendon or band-like. These are also known as aggressive fibromatosis or desmoid-type fibromatosis. Desmoid tumors often appear as infiltrative, usually well-differentiated, firm overgrowths of fibrous tissue, and they are locally aggressive.

Desmoid tumors can occur in any part of the body but most often occur in the abdomen, arms, and legs. These are generally not considered cancerous (malignant) because they do not spread to other body parts (metastasize); however, they can aggressively invade the surrounding tissue and can be very difficult to remove surgically. 

Desmoid Tumors Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Desmoid Tumors market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Desmoid Tumors market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Desmoid Tumors Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

Desmoid Tumors Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Desmoid Tumors market or expected to get launched during the study period. The analysis covers Desmoid Tumors market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Desmoid Tumors Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Key Therapeutic Developments in the Desmoid Tumors Market

On September 27, 2022, Ayala Pharmaceuticals, Inc. (Nasdaq: AYLA) announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track Designation to its therapy, AL102, for the treatment of progressing desmoid tumors. Earlier this month, at the ESMO Congress 2022, Ayala Pharmaceuticals presented positive interim data from RINGSIDE Pivotal Phase 2/3 Trial of AL102 in Desmoid Tumors.

Learn How Desmoid Tumors Market Will Evolve by 2032 @

Desmoid Tumors Therapeutics Analysis

There are approx. 12+ key companies which are developing therapies for Desmoid Tumors. Currently, SpringWorks Therapeutics has its Desmoid Tumors drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Desmoid Tumors Therapeutics Market include

• SpringWorks Therapeutics

• Iterion Therapeutics

• Cellestia Biotech

• BioSpecifics Technologies Corp.

• 180 Life Sciences

• AFT Pharma

• Timber Pharmaceuticals

• MedPacto

• Intas Pharmaceuticals

• Jina pharmaceuticals

And many others

Desmoid Tumors Drugs Covered in the report include:

• Nirogacestat: SpringWorks Therapeutics

• Tegavivint: Iterion Therapeutics

And many more 

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Desmoid Tumors Competitive Intelligence Analysis

4. Desmoid Tumors Market Overview at a Glance

5. Desmoid Tumors Disease Background and Overview

6. Desmoid Tumors Patient Journey

7. Desmoid Tumors Epidemiology and Patient Population (In US, EU5, and Japan)

8. Desmoid Tumors Treatment Algorithm, Current Treatment, and Medical Practices

9. Desmoid Tumors Unmet Needs

10. Key Endpoints of Desmoid Tumors Treatment

11. Desmoid Tumors Marketed Products

12. Desmoid Tumors Emerging Drugs and Latest Therapeutic Advances

13. Desmoid Tumors Seven Major Market Analysis

14. Attribute Analysis

15. Desmoid Tumors Market Outlook (In US, EU5, and Japan)

16. Desmoid Tumors Access and Reimbursement Overview

17. KOL Views on the Desmoid Tumors Market

18. Desmoid Tumors Market Drivers

19. Desmoid Tumors Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Acute Pancreatitis Market

“Acute Pancreatitis Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Acute Pancreatitis Market size, share, and trends in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States